Form 4: Veracyte CSO's Routine Tax Withholding on RSU Vesting

Veracyte's Chief Scientific and Medical Officer, Phillip G. Febbo, reported a routine disposition of shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Phillip G. Febbo, Veracyte, Inc.'s Chief Scientific & Medical Officer, reported a transaction on September 2, 2025.
• The transaction involved the disposition of 2,955 shares of common stock to satisfy tax withholding obligations.
• This disposition was in connection with the vesting of certain restricted stock units and does not represent a sale.
• The shares were valued at $30.11 per share for tax purposes.
• Following this transaction, Mr. Febbo beneficially owns 100,790 shares of Veracyte common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates RSU vesting, a positive compensation event for the executive, with the disposition being a routine tax matter rather than a market sale.

Positives

• The transaction indicates the vesting of restricted stock units, which is a positive event for the reporting person, Phillip G. Febbo, as it represents compensation becoming fully owned.
• The disposition was for tax withholding, not a market sale, suggesting continued long-term holding intent for the remaining shares.

Negatives

• A reduction of 2,955 shares in direct beneficial ownership for tax purposes, though routine, slightly decreases the insider's direct stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape analysis. It reflects standard compensation practices within the biotechnology and diagnostics sector.

Stakeholder Impact

• Shareholders: A minor, routine reduction in insider ownership due to tax withholding, which is generally not seen as a negative signal.
• Employees (specifically Phillip G. Febbo): The vesting of RSUs represents a realization of compensation, positively impacting the executive.

Key Dates

Keywords

Veracyte, VCYT, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Phillip G. Febbo, Chief Scientific Officer, Medical Officer